This study looks at the safety and effects of a new medicine called NKT2152 for people with advanced clear cell renal cell carcinoma (ccRCC), a type of kidney cancer. The study has two parts. In Phase 1, doctors will find the best dose for patients by giving the medicine once a day. In Phase 2, they will study how well the medicine works and how safe it is.
To join, patients must be 18 years or older, have advanced ccRCC that has not responded to standard treatments, and be able to swallow pills. They must also have a life expectancy of at least 3 months and meet other health criteria.
- **Study Duration**: Participation involves multiple visits over a few months.
- **Risks**: There might be side effects, as this is a new treatment.
- **Eligibility**: Patients must meet specific health and treatment criteria.
This study offers patients who have no other treatment options the opportunity to try a new therapy that may help manage their cancer.
How understandable was the trial content above?
Hard to understand
Easy to understand